{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:15:13Z","timestamp":1783635313336,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R 44DK101240"],"award-info":[{"award-number":["R 44DK101240"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK128364"],"award-info":[{"award-number":["R01DK128364"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["S10 OD 032203"],"award-info":[{"award-number":["S10 OD 032203"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["S10OD026922"],"award-info":[{"award-number":["S10OD026922"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["24PRE1201204"],"award-info":[{"award-number":["24PRE1201204"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jhepr.2026.101796","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:15:54Z","timestamp":1772093754000},"page":"101796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4\u03b1"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-493X","authenticated-orcid":false,"given":"Xinru","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nga","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert K.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-8618","authenticated-orcid":false,"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9677-8540","authenticated-orcid":false,"given":"Athan","family":"Kuliopulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101796_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhepr.2026.101796_bib2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepat"},{"key":"10.1016\/j.jhepr.2026.101796_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41575-024-00938-9","article-title":"Envisioning how to advance the MASH field","volume":"21","author":"Allen","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101796_bib4","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101796_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41573-021-00367-2","article-title":"Lipogenesis inhibitors: therapeutic opportunities and challenges","volume":"21","author":"Batchuluun","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhepr.2026.101796_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-024-03889-x","article-title":"Metabolic dysfunction-associated steatotic liver disease-induced changes in the antioxidant system: a review","volume":"99","author":"Svobodov\u00e1","year":"2025","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.jhepr.2026.101796_bib7","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.cmet.2023.10.009","article-title":"The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"Sawada","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2026.101796_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101796_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","author":"Stefan","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhepr.2026.101796_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108811","article-title":"Insights into the results of resmetirom trials: can a thyroid hormone receptor agonist be the holy grail of MASH therapy?","volume":"268","author":"Arvanitakis","year":"2025","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.jhepr.2026.101796_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/CIRCULATIONAHA.122.061010","article-title":"Low-density lipoprotein cholesterol is predominantly associated with atherosclerotic cardiovascular disease events in patients with evidence of coronary atherosclerosis: the Western Denmark Heart Registry","volume":"147","author":"Mortensen","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jhepr.2026.101796_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034364","article-title":"Blood lipids, lipoproteins, and apolipoproteins with risk of coronary heart disease: a prospective study among racially diverse populations","volume":"13","author":"Deng","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jhepr.2026.101796_bib13","article-title":"Impact of cardiometabolic risk factors on hepatic fibrosis and clinical outcomes in MASLD: a population-based multi-cohort study","volume":"7","author":"Park","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101796_bib14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","article-title":"Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease","volume":"15","author":"Min","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2026.101796_bib15","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101796_bib16","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/hep.32589","article-title":"PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference","volume":"76","author":"Shearer","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101796_bib17","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ni1525","article-title":"'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage","volume":"8","author":"Kaneider","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhepr.2026.101796_bib18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jid.2018.08.019","article-title":"PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models","volume":"139","author":"Barr","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jhepr.2026.101796_bib19","doi-asserted-by":"crossref","first-page":"23188","DOI":"10.1074\/jbc.M116.732743","article-title":"Targeting liver fibrosis with a cell-penetrating protease-activated receptor-2 (PAR2) pepducin","volume":"291","author":"Shearer","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhepr.2026.101796_bib20","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1073\/pnas.1017091108","article-title":"Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins","volume":"108","author":"Sevigny","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2026.101796_bib21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/nm.2461","article-title":"Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation","volume":"17","author":"Badeanlou","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101796_bib22","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1096\/fj.13-232702","article-title":"Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism","volume":"27","author":"Lim","year":"2013","journal-title":"FASEB J"},{"key":"10.1016\/j.jhepr.2026.101796_bib23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ajpath.2014.10.008","article-title":"Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice","volume":"185","author":"Wang","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhepr.2026.101796_bib24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.molmet.2019.08.019","article-title":"PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease","volume":"29","author":"Rana","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhepr.2026.101796_bib25","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nm760","article-title":"Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation","volume":"8","author":"Covic","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jhepr.2026.101796_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-0716-1752-6_21","article-title":"Lipopeptide pepducins as therapeutic agents","volume":"2383","author":"Michael","year":"2022","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jhepr.2026.101796_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1749-6632.2011.06039.x","article-title":"G protein-coupled receptor modulation with pepducins: moving closer to the clinic","volume":"1226","author":"Dimond","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jhepr.2026.101796_bib28","doi-asserted-by":"crossref","first-page":"W45","DOI":"10.1093\/nar\/gkae358","article-title":"ChIP-Atlas 3.0: a data-mining suite to explore chromosome architecture together with large-scale regulome data","volume":"52","author":"Zou","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhepr.2026.101796_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/ATVBAHA.110.217828","article-title":"Hepatic hepatocyte nuclear factor 4alpha is essential for maintaining triglyceride and cholesterol homeostasis","volume":"31","author":"Yin","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jhepr.2026.101796_bib30","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41589-020-0535-8","article-title":"TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome","volume":"16","author":"Olsen","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jhepr.2026.101796_bib31","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1128\/MCB.00297-06","article-title":"Mitogen-activated protein kinase-mediated disruption of enhancer-promoter communication inhibits hepatocyte nuclear factor 4alpha expression","volume":"26","author":"Hatzis","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2026.101796_bib32","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1128\/MCB.21.21.7320-7330.2001","article-title":"Regulatory mechanisms controlling human hepatocyte nuclear factor 4alpha gene expression","volume":"21","author":"Hatzis","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jhepr.2026.101796_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.842636","article-title":"Platelets in non-alcoholic fatty liver disease","volume":"13","author":"Dalbeni","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhepr.2026.101796_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ecl.2023.01.002","article-title":"Cardiovascular implications of metabolic dysfunction-associated fatty liver disease","volume":"52","author":"Ren","year":"2023","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jhepr.2026.101796_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/17425250802707342","article-title":"Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism","volume":"5","author":"Chiang","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jhepr.2026.101796_bib36","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/hep.31604","article-title":"Hepatocyte nuclear factor 4\u03b1 prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling (in mice)","volume":"73","author":"Xu","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101796_bib37","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fmed.2020.00544","article-title":"Bile acids and FXR: novel targets for liver diseases","volume":"7","author":"Stofan","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhepr.2026.101796_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12944-025-02485-x","article-title":"Deoxycholic acid ameliorates obesity and insulin resistance by enhancing lipolysis and thermogenesis","volume":"24","author":"Tuerhongjiang","year":"2025","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jhepr.2026.101796_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ydbio.2012.10.031","article-title":"Role of kruppel-like transcription factors in adipogenesis","volume":"373","author":"Wu","year":"2013","journal-title":"Dev Biol"},{"key":"10.1016\/j.jhepr.2026.101796_bib40","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2008.04.004","article-title":"The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease","volume":"135","author":"Miele","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101796_bib41","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2013.01.020","article-title":"Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis","volume":"58","author":"Bechmann","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101796_bib42","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/hep.29689","article-title":"New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases","volume":"67","author":"Win","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101796_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jhepr.2026.101796_bib44","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1126\/science.1158042","article-title":"Regulation of hepatic lipogenesis by the transcription factor XBP1","volume":"320","author":"Lee","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2026.101796_bib45","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2022.02.031","article-title":"Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101796_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s44324-024-00013-6","article-title":"Unlocking therapeutic potential: exploring cross-talk among emerging nuclear receptors to combat metabolic dysfunction in steatotic liver disease","volume":"2","author":"Antwi","year":"2024","journal-title":"npj Metab Health Dis"},{"key":"10.1016\/j.jhepr.2026.101796_bib47","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhepr.2026.101796_bib48","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1093\/nar\/gkg605","article-title":"Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN","volume":"31","author":"Farre","year":"2003","journal-title":"Nucleic Acids Res"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:24:39Z","timestamp":1783632279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926000674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2589555926000674"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101796","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coagulation protease-activated receptor-2 (PAR2) promotes dyslipidemia, obesity and MASLD through repression of the hepatic pioneer factor HNF4\u03b1","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101796","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101796"}}